MARKET WATCH: Moderna Stock Tumbles Despite 42% Cancer Vaccine Success in Melanoma Trial...

Moderna's experimental melanoma vaccine showed a 42% reduction in recurrence or death over two years—a meaningful result that could expand the biotech company's pipeline beyond its core COVID business into personalized cancer treatments. But investor enthusiasm was tempered by an embargo breach that let news leak early, likely shifting the market reaction from a potential rally to immediate profit-taking. The incident highlights how tightly controlled pharmaceutical announcements are, and how any deviation can spook shareholders who may have already priced in the good news.